Tumor Biol. (2014) 35:11467–11472 DOI 10.1007/s13277-014-2459-y
RESEARCH ARTICLE
Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer Chuanli Ren & Yong Chen & Chongxu Han & Deyuan Fu & Hui Chen
Received: 25 June 2014 / Accepted: 6 August 2014 / Published online: 16 August 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract Interleukin-11 (IL-11) affects inflammation, motility, and invasion in cancer. Here, we investigated the clinical significance of plasma IL-11 (IL-11p) levels in patients with pancreatic cancer. We enrolled 44 patients with pathologically confirmed diagnoses of pancreatic cancer into this study (median age at diagnosis, 68 years; range, 42–86 years), along with 30 age- and sex-matched healthy controls and 3 patients with pancreatitis complicated with pancreatic cysts and 15 patients with early pancreatitis. Median baseline IL-11p levels of patients with pancreatic cancer were significantly higher C. Ren : C. Han Clinical Medical Testing Laboratory, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China Y. Chen Department of Oncology, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China D. Fu Department of Breast Oncology Surgery, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China H. Chen (*) Department of Geriatric Medicine, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, No. 98 Western Nantong Road, Yangzhou 225001, China e-mail: [email protected] C. Ren Department of Epidemiology and Biostatistics, Ministry of Education (MOE) Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing 211166, China C. Ren Section of Clinical Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing 211166, China
than that of the healthy controls (P0.05), but patients with distant metastases had lower median IL-11p values than did patients without distant metastases (P=0.043). Patients with IL-11p higher than the median level (43.2 pg/mL) had better prognoses than those with lower values (P=0.004), particularly as IL11p concentration increased to ≥50 pg/mL (P=0.001). IL-11p concentration correlated with overall survival (≥median IL11p, 10 months;
RESEARCH ARTICLE
Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer Chuanli Ren & Yong Chen & Chongxu Han & Deyuan Fu & Hui Chen
Received: 25 June 2014 / Accepted: 6 August 2014 / Published online: 16 August 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract Interleukin-11 (IL-11) affects inflammation, motility, and invasion in cancer. Here, we investigated the clinical significance of plasma IL-11 (IL-11p) levels in patients with pancreatic cancer. We enrolled 44 patients with pathologically confirmed diagnoses of pancreatic cancer into this study (median age at diagnosis, 68 years; range, 42–86 years), along with 30 age- and sex-matched healthy controls and 3 patients with pancreatitis complicated with pancreatic cysts and 15 patients with early pancreatitis. Median baseline IL-11p levels of patients with pancreatic cancer were significantly higher C. Ren : C. Han Clinical Medical Testing Laboratory, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China Y. Chen Department of Oncology, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China D. Fu Department of Breast Oncology Surgery, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, Yangzhou 225001, China H. Chen (*) Department of Geriatric Medicine, Northern Jiangsu People’s Hospital and Clinical Medical College of Yangzhou University, No. 98 Western Nantong Road, Yangzhou 225001, China e-mail: [email protected] C. Ren Department of Epidemiology and Biostatistics, Ministry of Education (MOE) Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing 211166, China C. Ren Section of Clinical Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing 211166, China
than that of the healthy controls (P0.05), but patients with distant metastases had lower median IL-11p values than did patients without distant metastases (P=0.043). Patients with IL-11p higher than the median level (43.2 pg/mL) had better prognoses than those with lower values (P=0.004), particularly as IL11p concentration increased to ≥50 pg/mL (P=0.001). IL-11p concentration correlated with overall survival (≥median IL11p, 10 months;
